Delving into the Latest Updates on Autologous bone marrow derived mesenchymal stem cells (Nipro Corproration) with Synapse

Overview

Basic Info

Drug Type

Mesenchymal stem cell therapy

Synonyms

Autologous bone marrowderived mesenchymal stem cells (MSCs) therapy Nipro Corproration, Stemirac, ステミラック注

Target-

Mechanism

Cell replacements

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication

Spinal Cord Injuries

Inactive Indication-

Originator Organization

Sapporo Medical University

Nipro Corp.

Active Organization

Nipro Corp.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

JP (28 Dec 2018),

Spinal Cord Injuries

Regulation-

Login to view timeline

In this section, new arsenals for neurological treatment based on an open source are introduced. "Delytact" and "Stemirac" are discussed in this section. These two new arsenals have been accepted as cell and gene therapy products by the Ministry of Health, Labor, and Welfare. "Delytact" is a viral-gene therapy that targets malignant brain tumors, such as malignant gliomas, while "Stemirac" targets against spinal contusion via self-mesenchymal implantation. Both are permitted clinical arsenals in Japan.

100 Deals associated with Autologous bone marrow derived mesenchymal stem cells (Nipro Corproration)

Login to view more data